« Return to News | Awards & Advancement

Kinsey joins Fraunhofer CSE as director of photovoltaic technologies

Friday, June 8, 2012 11:32 AM

The Fraunhofer Center for Sustainable Energy Systems (CSE), an applied contract R&D center of Cambridge, Mass., has hired concentration photovoltaics (CPV) expert Geoffrey S. Kinsey, Ph.D. to serve as the new director of its photovoltaic technologies group.

Kinsey previously served as senior director of R&D at Amonix, where he led a team optimizing operation of Amonix solar power generators using III-V multijunction cells. Recently, this group became the first to demonstrate a module efficiency rating of 33% in outdoor operating conditions. Prior to his position at Amonix, he served as the technical lead for CPV products at Boeing-Spectrolab, where he spent seven years in R&D of high-efficiency multijunction cells for both space and terrestrial applications.

At Fraunhofer CSE, Kinsey will oversee development of strategy for the photovoltaic research group, and the execution of research plans and contracts, as well as business development. His responsibility includes the center's indoor PV module fabrication and testing laboratory in Cambridge and outdoor PV test facilities in Revere, Mass., and Albuquerque, N.M.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.